VRTX — VERTEX PHARMACEUTICALS INC / MA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 875320 ·
Last close
$491.34
Market Cap
$124.70B
52W High
$503.89
52W Low
$412.27
ADV30
1,658,180
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,986,900,000 | 2,594,100,000 | 1,138,800,000 | 1,031,400,000 | 26,484,400,000 | 5,492,900,000 | 7,122,500,000 |
| Dec 2025 | 3,190,000,000 | 2,724,000,000 | 1,130,300,000 | 1,191,100,000 | 25,643,000,000 | 5,084,800,000 | 6,977,200,000 |
| Sep 2025 | 3,076,400,000 | 2,661,600,000 | 1,238,800,000 | 1,082,900,000 | 24,862,300,000 | 4,939,600,000 | 7,543,500,000 |
| Jun 2025 | 2,964,700,000 | 2,557,200,000 | 1,154,200,000 | 1,032,900,000 | 24,036,700,000 | 4,972,200,000 | 6,861,300,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,240,600,000
Investing CF
$-1,321,500,000
Financing CF
$-2,119,700,000
CapEx
$-530,300,000
Dividends Paid
—
Buybacks
$-2,256,100,000
EPS Diluted TTM
$16.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$14,591,400,000
Inventory
$1,766,700,000
Receivables
$1,996,100,000
ST Investments
$1,753,800,000
EBIT TTM
$5,061,900,000
Pretax Income TTM
$5,165,700,000
Interest Exp TTM
$10,300,000
Analysts
28
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,218,000,384
EBITDA
$4,981,199,872
Free Cash Flow
$2,783,225,088
Enterprise Value
$119,444,553,728
Total Cash
$7,246,700,032
Total Debt
$1,986,499,968
Shares Out
253,805,417
Trailing EPS
$16.85
Book Value
$76.18
ROE
24.2%
ROA
12.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,001,300,000 | 4,554,400,000 | 3,953,200,000 | 25,643,000,000 | 6,977,200,000 | — | 3,631,400,000 |
| Dec 2024 | 11,020,100,000 | -233,400,000 | -535,600,000 | 22,533,200,000 | 6,123,600,000 | — | -492,600,000 |
| Dec 2023 | 9,869,200,000 | 3,780,400,000 | 3,619,600,000 | 22,730,200,000 | 5,149,800,000 | — | 3,537,300,000 |
| Dec 2022 | 8,930,700,000 | 4,249,900,000 | 3,322,000,000 | 18,150,900,000 | 4,238,200,000 | — | 4,129,900,000 |
TTM Snapshot
Revenues TTM
$9,573,800,000
NetIncome TTM
$3,863,100,000
OpCashFlow TTM
$0
Assets (Latest)
$22,533,200,000
Forward EPS
$21.47
Max Pain — expiry 2026-07-17
max pain strike: $460.00 · spot: $492.24 · call oi: 4,574 · put oi: 3,413Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | $117.46B | $57.52 | — |
| PFE | PFIZER INC | $138.44B | $24.29 | — |
| GSK | GSK plc | $105.17B | $52.50 | — |
| SNY | Sanofi | $102.81B | $42.95 | — |
| SNYNF | Sanofi | $101.95B | $85.18 | — |
News headlines (Yahoo Finance, 1h cache)
Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight
2026-06-29 14:31 · Yahoo
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-27 10:20 · Yahoo
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
2026-06-26 21:50 · Yahoo
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project
2026-06-24 14:00 · Yahoo
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
2026-06-23 15:50 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable
2026-06-23 13:12 · Yahoo
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
2026-06-23 12:08 · Yahoo
2 Reasons to Like VRTX (and 1 Not So Much)
2026-06-22 17:55 · Yahoo
3 of Wall Street’s Favorite Stocks to Consider Right Now
2026-06-22 12:51 · Yahoo
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
2026-06-20 06:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.